Molecular Partners (NASDAQ:MOLN) Shares Down 0.7% - Here's Why

Key Points

• Molecular Partners AG (NASDAQ:MOLN) saw a stock price decrease of 0.7% to $3.54 with significantly increased trading volume, indicating heightened interest among investors.
• The company reported a quarterly earnings loss of ($0.50) EPS, missing analyst expectations of ($0.39) by ($0.11), reflecting ongoing financial challenges.
• An institutional investor, Suvretta Capital Management LLC, significantly increased its stake in Molecular Partners by 455.4%, acquiring over 2.2 million shares, suggesting confidence in the company's future prospects.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) shares traded down 0.7% during trading on Thursday . The stock traded as low as $3.46 and last traded at $3.54. 3,190 shares were traded during trading, an increase of 245% from the average session volume of 924 shares. The stock had previously closed at $3.56.

Molecular Partners Trading Up 0.4%

The company has a 50 day simple moving average of $3.70 and a 200 day simple moving average of $4.06. The stock has a market capitalization of $142.73 million, a PE ratio of -1.84 and a beta of 1.10.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.11). On average, equities research analysts predict that Molecular Partners AG Sponsored ADR will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. Suvretta Capital Management LLC increased its position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) by 455.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,221,494 shares of the company's stock after buying an additional 1,821,494 shares during the quarter. Suvretta Capital Management LLC owned about 5.50% of Molecular Partners worth $10,548,000 as of its most recent filing with the Securities and Exchange Commission. 26.55% of the stock is owned by institutional investors and hedge funds.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.